


Highlights 2017/4-2018/3

Financial/Non-Financial Highlights


Financial Information

Revenue (Millions of Yen)




Increased by 7.0% year-on-year due to increased royalty revenue and expanded sales of new key products offsetting the negative impact of the OPDIVO price cut in Japan.

Operating profit (Millions of Yen)




Decreased by 16.0% year-on-year mainly due to increased R&D costs and SG&A expenses, and reaction to the patent infringement litigation settlement revenue posted in the previous year.

Profit for the year attributable to owners of the parent company (Millions of Yen)




Net financial income improved from the previous year but the profit before tax decreased by 9.9% compared to the previous year due to decreased operating profit.

R&D costs / Ratio to revenue (Millions of Yen / %)




Increased by 19.7% compared to the previous year due to increased OPDIVO-related clinical trials, sponsored research projects and research collaborations in active pursuit of R&D activities.

Basic earnings per share (Yen)




Dividend per share (Yen)



ONO considers the redistribution of profits to shareholders as a vital management policy. ONO will prioritize stable dividend distribution, making appropriate distribution of its profits in line with its business performance.

Non-Financial Information


Number of employees



We recruit not only new graduates but also midcareer workers and others from a variety of different backgrounds to strengthen our corporate infrastructure.

▶ Human Resources and Human Rights, p. 041


Number of female employees / Ratio of female to male workforce



We direct our strong endeavors in creating systems that enable women to flourish. Thanks to efforts we have made, female employees have increased in number across all divisions since 2011.

▶ Human Resources and Human Rights, p. 041


Participation record for "Relay For Life" as part of CSR activities



Since FY2014, we have enthusiastically participated in "Relay For Life," a charity event aimed at supporting cancer patients and their families and making cancer controllable and surmountable through community action against cancer. Both the frequency of participation and the number of participants have increased year by year.

▶ Society, p. 045


Meetings with institutional investors (personal interviews/phone conferences)



We disseminate information based on the policy of pursuing accuracy, fairness, impartiality, and promptness. We actively hold personal interviews and phone conferences with investors inside and outside Japan.

▶ Information Disclosure, p. 034


Comprehensive medical examination rate (February 2018)



We take a top-down approach to actively maintaining and enhancing the health of employees and their families. We have a support system in place for disease prevention, early detection, and treatment.

▶ Promotion of Health and Productivity Management, p. 044

Energy-derived CO₂ emissions (10,000 tons-CO₂)



We have formulated a voluntary environmental action plan. Under the plan, we set and work to achieve numerical targets. Sites where data were collected: Fujiyama Plant, Joto Plant, Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute.

▶ The Environment, p. 047